Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches

ELI LILLY & Co

2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.
2023 reported EPS $7.65-$7.85; non-GAAP EPS $8.10-$8.30; 2022 reaffirmed $6.50-$6.65 reported.
Plans to launch donanemab, mirikizumab, lebrikizumab, pirtobrutinib; potential tirzepatide obesity submission.
Fifth consecutive 15% annual dividend increase; R&D spend $8.2B-$8.4B vs $7.1B-$7.3B 2022.
Gross margin ~77% reported, ~79% non-GAAP; tax rate ~16%; Alimta LOE and FX headwinds.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELI LILLY & Co reported FY2023 results: revenue $30.3 billion to $30.8 billion, EPS $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.

Period: FY2023
Revenue: $30.3 billion to $30.8 billion
EPS: $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis
Result: guidance update

Exact text from the filing

2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products. • 2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELI LILLY & Co reported FY2022 results: revenue $28.5 to $29.0 billion, EPS $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis. Guidance reaffirmed.

Period: FY2022
Revenue: $28.5 to $29.0 billion
EPS: $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

IPR&D or development milestone charges incurred during Q4 2022. 2 The company reaffirmed its 2022 financial guidance, as set forth in the following table: 2022 Guidance Revenue $28.5 to $29.0 billion Gross Margin % of Revenue (reported) Approx. 76% Gross Margin % of Revenue (non-GAAP) Approx. 78% Marketing, Selling & Administrative $6.4 to $6.6 billion

View on SEC.gov

Browse all earnings releases →

ELI LILLY & Co filing history →

Source: SEC EDGAR

accession 0000059478-22-000277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.